Solvay Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LUVOX® CR (fluvoxamine maleate) Extended-Release Capsules for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adults.
The American Psychiatric Association applauds recent Congressional efforts led by Rep. Danny Davis, D-Ill., to improve treatment for the large number of people with mental illnesses and substance use disorders who are currently incarcerated in U.S. jails and prisons. The U.S. Senate passed the Second Chance Act (H.R. 1593) this week by unanimous consent. The U.S. House of Representatives passed the legislation last fall.
What is mindfulness? Why do we need it? And what does it have to do with therapy?